Hostname: page-component-745bb68f8f-hvd4g Total loading time: 0 Render date: 2025-01-14T20:08:40.358Z Has data issue: false hasContentIssue false
  • English
  • Français

No Correlation between Neuroleptic-induced Increase of β-Endorphin Serum Level and Therapeutic Efficacy in Schizophrenia

Published online by Cambridge University Press:  29 January 2018

D. Naber ,
N. Nedopil  and
E. Eben
D. Naber*
Affiliation:
Psychiatric Hospital, University of Munich, Nussbaumstr, 7, 8000 Munich 2, West-Germany
N. Nedopil
Affiliation:
Psychiatric Hospital, University of Munich
E. Eben
Affiliation:
Psychiatric Hospital, University of Munich
*
∗Correspondence.
Get access Rights & Permissions [Opens in a new window]

Summary

In 23 acute, unmedicated, schizophrenic patients, psychotic behaviour and β-endorphin serum level were measured before and during four weeks of neuroleptic therapy. Prior to drug treatment, β-endorphin level of all patients was within the normal range. Neuroleptic therapy induced marked elevations of β-endorphin in eight subjects; statistical analysis revealed a slight but significant increase for the whole group. This endocrine effect was not correlated with therapeutic efficacy of neuroleptic treatment.

Type
Papers
Information
The British Journal of Psychiatry , Volume 144 , Issue 6 , June 1984 , pp. 651 - 653
Copyright
Copyright © 1984 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Berger, P. A., Watson, S. J., Am, H., Elliott, G. R., Rubin, R. T., Pfefferbaum, A., Davis, K. L., Barchas, J. D. & Li, C. H. (1980) β-Endorphin and schizophrenia. Archives of General Psychiatry, 37, 635–40.Google Scholar
Bloom, F., Segal, D., Ling, N. & Guillemin, R. (1976) Endorphins: Profound behavioral effects in rats suggest new etiological factors in mental illness. Science, 194, 630–2.CrossRefGoogle ScholarPubMed
Brambilla, F., Genazzani, A. R., Facchinetti, F., Parrini, D., Petraglia, F., Sacchetti, E., Scarone, S., Guastalla, A. & D'Antona, N. (1981) β-Endorphin and β-lipoprotein plasma levels in chronic schizophrenia, primary affective disorders and secondary affective disorders. Psychoneuroendocrinology, 6, 321–30.Google Scholar
Davis, G. C., Bunney, W. E. Jr., De Fraites, E. G., Kleinman, J. E., Van Kammen, D. P., Post, R. M. & Wyatt, R. J. (1977) Intravenous naloxone administration in schizophrenia and affective disorder, Science, 197, 74–7.Google Scholar
Emrich, H. M. (1981) The Rote of Endorphins in Neuropsychiatry. Basel: S. Karger.Google Scholar
Emrich, H. M., Höllt, V., Bergmann, M., Kissling, W., Schmid, W., Von Zerssen, D. & Herz, A. (1980) Plasma levels of β-endorphin in schizophrenic patients: Failure of naloxone to counteract curative effects of neuroleptic drugs. In Neural Peptides and Neuronal Communications (eds, Costa E. and Trabucchi M.). New York: Raven Press.Google Scholar
Emrich, H. M., Höllt, V., Kissling, W., Fischler, M., Laspe, H., Heinemann, H., Von Zerssen, D. & Herz, A. (1979) β-Endorphin-like immunoreactivity in cerebrospinal fluid and plasma of patients with schizophrenia and other neuropsychiatric disorders. Pharmakopsychiatria, 12, 267–74.Google Scholar
Gerner, R. H., Catlin, D. H., Gorelick, D. A., Hut, K. K. & Li, C. H. (1980) β-Endorphin. Intravenous infusion causes behavioral change in psychiatric in-patients. Archives of Central Psychiatry, 37, 642–7.Google Scholar
Gerner, R. H. & Sharp, B. (1982) CSF β-endorpbin-immunoreactivity in normal, schizophrenic, depressed, manic and anorexic subjects. Brain Research, 237, 244–7.Google Scholar
Giraud, P., Lissitzky, J. C., Conte-Delvox, B., Gillioz, P. & Oliver, C. (1980) Influence of haloperidol on ACTH and β-endorphin secretion in the rat. European Journal of Pharmacology, 62, 215–17.Google Scholar
Hôllt, V. & Bergmann, M. (1982) Effects of acute and chronic haloperidol treatment on the concentrations of immunoreactive β-endorphin in plasma, pituitary, and brain of rats. Neuropharmacology, 21, 147–54.Google Scholar
Houck, J. C., Kimball, C., Chang, C., Pedigo, N. W. & Yamamura, H. I. (1980) Placental β-endorphin-like peptides. Science, 207, 78–80.CrossRefGoogle ScholarPubMed
Jaquet, Y. & Marks, N. (1976) The c-fragment of β-lipotropin: an endogenous neuroleptic or antipsychotogen. Science, 194, 632–5.Google Scholar
Naber, D., Wire-Justice, A. & Kafka, M. S. (1982) Chronic fluphenazine treatment modifies cireadian rhythms of neurotransmitter receptor binding in rat brain. Journal of Neurotransmission, 55, 277–88.Google Scholar
Rimon, R., Terenius, L., Averbuch, I. & Belmaker, R. H. (1983) High-dose haloperidol increases CSF opioid activity in patients with chronic schizophrenia. Pharmakopsychiatria, 16, 9–12.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.